Table 2.
The number of analyzed patients and revealed p53-related DEGs in 27 AML subtypes
| AML subtypes | Number of patients included in analysis | Number of p53-related DEGs |
|---|---|---|
| Cytogenetic groups | ||
| Normal | 290 | 147* |
| t (15;17) | 34 | 172* |
| t (8;21) | 39 | 202* |
| inv (16) | 37 | 147* |
| 11q23 | 10 | 165* |
| -5/7 (q) | 31 | 102* |
| trisomy 8 | 26 | 109* |
| Complex | 23 | 104* |
| t (6;9) | 5 | 176* |
| t (9;22) | 3 | 78 |
| -9(q) | 7 | 88 |
| FAB groups | ||
| M0 | 48 | 145* |
| M1 | 136 | 90* |
| M2 | 157 | 37 |
| M3 | 34 | 172* |
| M4 | 108 | 39 |
| M4E | 5 | 185* |
| M5 | 110 | 68* |
| M6 | 9 | 42 |
| Molecular mutations | ||
| FLT3-ITD | 132 | 128* |
| FLT3-TKD | 46 | 64 |
| NPM1 | 154 | 151* |
| CEBPA | 33 | 97 |
| NRAS | 44 | 143* |
| KRAS | 4 | 171* |
| EV1 | 28 | 163* |
| RUNX1 | 11 | 143* |
| Total number of patients | 607 | |
*significant enrichment (p-value <0.01) for p53 pathway-related genes